




A. SCLC Molecular Subtypes



B. Subtype-Specific Drug Recommendations



C. Subtype-Guided Treatment Algorithm



Consider: OXPHOS inhibitors (all subtypes)

D. Key Clinical Trials by Subtype

Subtype	Drug	Trial	Phase	Status
SCLC-A	Tarlatamab	DeLLphi-301	III	Enrolling
SCLC-A	Alisertib	NCT02038647	II	Completed
SCLC-N	Olaparib+TMZ	NCT02446704	I/II	Active
SCLC-P	Erdafitinib	NCT03827850	II	Recruiting
SCLC-I	Atezo+Tira	SKYSCRAPER-02	III	Results 2024
All	IACS-010759	NCT02882321	I	OXPHOS target